FIBROGEN INC (30)

Browse by Contract Category

Contracts

Amended and Restated Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of January 21, 2022 (Filed With SEC on May 9, 2022)
Amendment No. 4 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of October... (Filed With SEC on February 28, 2022)
Transition Agreement by and between FibroGen, Inc. and Pat Cotroneo, dated as of August 14, 2021 (Filed With SEC on November 9, 2021)
Offer Letter by and between FibroGen, Inc. and Juan Graham, effective as of July 30, 2021 (Filed With SEC on November 9, 2021)
Sixth Amendment to the Lease by and between ARE-San Francisco No., 43, LLC and FibroGen, Inc. as of June 1, 2021 (Filed With SEC on August 9, 2021)
Description of Capital Stock of FibroGen, Inc (Filed With SEC on March 2, 2020)
Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of July 16, 2021 (Filed With SEC on November 9, 2021)
Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), as of June 16, 2021 (Filed With SEC on August 9, 2021)
Amendment No. 3 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of January... (Filed With SEC on May 10, 2021)
Astellas EU Supply Agreement by and between FibroGen, Inc. and Astellas Pharma Europe Ltd, effective as of January 1, 2021 (Filed With SEC on May 10, 2021)
Transition, Separation, and Consulting Agreement by and between FibroGen, Inc. and K. Peony Yu, dated as of November 27, 2020 (Filed With SEC on May 10, 2021)
Offer Letter, by and between FibroGen, Inc. and Mark Eisner, dated as of October 22, 2020 (Filed With SEC on March 1, 2021)
Product Specific Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020 (Filed With SEC on March 1, 2021)
Master Services Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020 (Filed With SEC on March 1, 2021)
Collaboration Agreement by and between FibroGen, Inc. and Astellas Pharma Inc., effective June 1, 2005 (Filed With SEC on November 5, 2020)
Amendment No. 1 to the Amended and Restated License, Development and Commercialization Agreement by and between FibroGen, Inc. and AstraZeneca AB, effective as of July 1, 2020 (Filed With SEC on August 6, 2020)
Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development... (Filed With SEC on August 6, 2020)
Amendment No. 1 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective as of May... (Filed With SEC on August 6, 2020)
Offer Letter, by and between FibroGen, Inc. and Thane Wettig, dated as of May 7, 2020 (Filed With SEC on August 6, 2020)
FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 7, 2020)
Form of Executive Officer Change in Control and Severance Agreement (Filed With SEC on March 2, 2020)
Offer Letter, by and between FibroGen, Inc. and Enrique Conterno, dated as of December 17, 2019 (Filed With SEC on March 2, 2020)
Offer Letter, by and between FibroGen, Inc. and Elias Kouchakji, dated as of January 24, 2014 (Filed With SEC on March 2, 2020)
Offer Letter, by and between FibroGen, Inc. and Christine Chung, dated as of June 17, 2008 (Filed With SEC on March 2, 2020)
Commercial Supply Agreement by and between FibroGen, Inc. and Catalent Pharma Solutions, LLC, effective as of January 1, 2020 (Filed With SEC on March 2, 2020)
Offer Letter, by and between FibroGen, Inc. and James Schoeneck, dated September 18, 2019 (Filed With SEC on November 12, 2019)
FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on November 12, 2019)
FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on August 8, 2019)
Amendment No. 33 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of January... (Filed With SEC on May 9, 2019)
Amendment No. 1 to Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of January 1, 2013 (Filed With SEC on February 27, 2019)